US 11,753,628 B2
HSD17B13 variants and uses thereof
Noura S. Abul-Husn, Tarrytown, NY (US); Omri Gottesman, Tarrytown, NY (US); Alexander Li, Tarrytown, NY (US); Xiping Cheng, Tarrytown, NY (US); Yurong Xin, Tarrytown, NY (US); Jesper Gromada, Tarrytown, NY (US); Frederick E. Dewey, Tarrytown, NY (US); Aris Baras, Tarrytown, NY (US); and Alan Shuldiner, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Mar. 31, 2022, as Appl. No. 17/709,965.
Application 17/709,965 is a continuation of application No. 15/875,192, filed on Jan. 19, 2018.
Claims priority of provisional application 62/581,918, filed on Nov. 6, 2017.
Claims priority of provisional application 62/472,972, filed on Mar. 17, 2017.
Claims priority of provisional application 62/449,335, filed on Jan. 23, 2017.
Prior Publication US 2022/0267743 A1, Aug. 25, 2022
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 9/04 (2006.01); C12N 15/113 (2010.01); C12Q 1/6883 (2018.01); A61K 31/713 (2006.01); G01N 33/50 (2006.01); C12Q 1/32 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6876 (2018.01); A61K 47/61 (2017.01); A61P 1/16 (2006.01); A61K 38/44 (2006.01); A61K 38/46 (2006.01); C12N 9/22 (2006.01); C12N 9/96 (2006.01); C12N 15/11 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01); A61K 48/00 (2006.01)
CPC C12N 9/0006 (2013.01) [A61K 31/713 (2013.01); A61K 38/443 (2013.01); A61K 38/465 (2013.01); A61K 47/61 (2017.08); A61P 1/16 (2018.01); C12N 9/22 (2013.01); C12N 9/96 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12Q 1/32 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6876 (2013.01); C12Q 1/6883 (2013.01); C12Y 101/01051 (2013.01); C12Y 101/01062 (2013.01); G01N 33/5067 (2013.01); A61K 48/00 (2013.01); A61K 48/0066 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2320/34 (2013.01); C12N 2800/24 (2013.01); C12N 2800/80 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4704 (2013.01); G01N 2800/085 (2013.01)] 26 Claims
 
1. A method of treating a subject who is not a carrier of the HSD17B13 rs72613567 variant and has a chronic liver disease, the method comprising introducing into the subject an antisense molecule that hybridizes to an HSD17B13 nucleic acid molecule and decreases expression of HSD17B13 in a liver cell in the subject.